Trial Profile
A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM-101 Compared to Oral Levofloxacin in the Treatment of Patients With Community-Acquired Bacterial Pneumonia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2019
Price :
$35
*
At a glance
- Drugs Solithromycin (Primary) ; Levofloxacin
- Indications Bacterial infections; Community-acquired pneumonia
- Focus Therapeutic Use
- Sponsors Cempra Pharmaceuticals
- 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
- 31 Mar 2012 Results to be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2012)
- 18 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.